ISPOR - Cost-Effectiveness of Rivaroxaban and Aspirin Compared to Aspirin Alone in Patients with Stable Cardiovascular Disease- An Australian Perspective

Full Text

Cost-Effectiveness of Rivaroxaban and Aspirin Compared to Aspirin Alone in Patients with Stable Cardiovascular Disease- An Australian Perspective

Abstract

Authors

Z Ademi E Zomer A Tonkin D Liew

Back to Volume 21, Supplemental S2

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now